Impediment and risk of acute renal failure in acute pancreatitis patients | Abstract
international journal of bioassays.
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Impediment and risk of acute renal failure in acute pancreatitis patients

Author(s): Naresh Pahwa*, Neeraj Jain, Ravindra Kumar, Urvi Waghela, Susmit Kosta, Rupchandra Patidar


The present study is focused on the involvement and risk of acute kidney injury in acute pancreatitis patients. We are looking back to the assessed acute pancreatitis patients who presented to our hospital over a period of two years. In the period of study, 382 AP patients were presented to department of medicine. 370 patients (96.8%) were found pancreatic lesion with inflammation, 296 patients (77.5%) were found pancreatic cyst with fluid, 75 patients (19.6%) were found with renal failure, 38 patients (9.95%) were found with respiratory failure, 26 patients (6.81%) were found with pleural effusion. multiple organs failure was found in 40 (10.4) patients. 281 (73.6%) patients had more than a threefold increase in serum amylase and lipase levels. 171 patients were diabetic (44.8%), 80 patients were hypertensive (20.94%) and 100 patients were alcoholic (26.2%). Among the 75 ARF patients, 50 required temporary HD and returned to their baseline kidney function over a period of 3-4 weeks. 20 patients were died out of which 18 patients had acquired renal failure. In conclusion acute pancreatitis when coupled with acute renal failure have high mortality rate.

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.

International Journal of Bioassays [ISSN: International Journal of Bioassays] is licensed under
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Copyright 2012-2024. All rights reserved.